News Center

ACELYRIN, INC. Furthers Leadership Position in Immunology with Transformative Acquisition of ValenzaBio

ACELYRIN, INC. to Accelerate Development of Izokibep in Hidradenitis Suppurativa

Former Merck Commercial President Dawn Svoronos joins ACELYRIN, INC. Board of Directors

ACELYRIN, INC. Adds Two Veteran C-suite Leaders

ACELYRIN, INC. Announces Phase 2 Data for Izokibep in Psoriatic Arthritis That Demonstrate Broad Clinical Efficacy – including in Difficult-to-Treat Manifestations – Driving Meaningful Benefits for Patients Such as Improved Pain, Sleep, and Physical Function

ACELYRIN, INC. to Present at Upcoming Investor Conferences

ACELYRIN, INC. Announces $300 Million Series C Financing to Accelerate Phase 3 Development of Izokibep, a Unique IL-17A Inhibitor to Treat Inflammatory Diseases

ACELYRIN, INC. Appoints Biotechnology Veteran Gil M. Labrucherie as Chief Financial Officer